Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Biochimica Et Biophysica Acta
Karen M SmithRobert J Ferrante

Abstract

There is substantial evidence that a bioenergetic defect may play a role in the pathogenesis of Huntington's Disease (HD). A potential therapy for remediating defective energy metabolism is the mitochondrial cofactor, coenzyme Q10 (CoQ10). We have reported that CoQ10 is neuroprotective in the R6/2 transgenic mouse model of HD. Based upon the encouraging results of the CARE-HD trial and recent evidence that high-dose CoQ10 slows the progressive functional decline in Parkinson's disease, we performed a dose ranging study administering high levels of CoQ10 from two commercial sources in R6/2 mice to determine enhanced efficacy. High dose CoQ10 significantly extended survival in R6/2 mice, the degree of which was dose- and source-dependent. CoQ10 resulted in a marked improvement in motor performance and grip strength, with a reduction in weight loss, brain atrophy, and huntingtin inclusions in treated R6/2 mice. Brain levels of CoQ10 and CoQ9 were significantly lower in R6/2 mice, in comparison to wild type littermate control mice. Oral administration of CoQ10 elevated CoQ10 plasma levels and significantly increased brain levels of CoQ9, CoQ10, and ATP in R6/2 mice, while reducing 8-hydroxy-2-deoxyguanosine concentrations, a marker...Continue Reading

References

Jun 1, 1992·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·R E Beyer
Jun 29, 1990·Biochemical and Biophysical Research Communications·V KaganL Packer
Nov 24, 1999·Free Radical Biology & Medicine·M TomasettiR Alleva
Jan 10, 2002·Nature·Karim S EchtayMartin D Brand
Jan 2, 2003·Nature Reviews. Drug Discovery·Brian P Zambrowicz, Arthur T Sands
Feb 18, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Peter H TangKevin Bove
Nov 10, 2004·Neurology·J M ShefnerUNKNOWN NEALS Consortium
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Steven M Hersch, Robert J Ferrante
Jun 7, 2005·Expert Opinion on Emerging Drugs·Hoon Ryu, Robert J Ferrante
Sep 24, 2005·Annals of Neurology·M Flint Beal
Sep 27, 2005·Journal of Neurochemistry·Jeremy M Van RaamsdonkBlair R Leavitt
Dec 14, 2005·Neurology·K L FerranteM Cudkowicz

❮ Previous
Next ❯

Citations

Feb 8, 2008·Bulletin of Experimental Biology and Medicine·L D Luk'yanovaA T Proshin
Sep 5, 2012·Molecular Neurobiology·Pawel M SwitonskiMaciej Figiel
Aug 16, 2008·Archives of Pharmacal Research·Rengarajan BaskaranBong Kyu Yoo
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Steven M Hersch, H Diana Rosas
Oct 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·Vanita ChopraSteven Hersch
Jul 31, 2013·Proceedings of the National Academy of Sciences of the United States of America·Irini ManoliCharles P Venditti
Jan 19, 2010·The Journal of Biological Chemistry·Jayne E TelfordGavin P Davey
Jul 28, 2010·Human Molecular Genetics·Jinho KimRobert J Ferrante
Aug 24, 2012·Human Molecular Genetics·Linda MøllersenArne Klungland
Feb 28, 2009·PloS One·Elsa DiguetEmmanuel Brouillet
Dec 8, 2009·Neuropsychiatric Disease and Treatment·Meredith SpindlerClaire Henchcliffe
Feb 6, 2014·The International Journal of Biochemistry & Cell Biology·I P Hargreaves
Dec 12, 2012·Biomarkers in Medicine·Annie Killoran, Kevin M Biglan
Nov 5, 2015·Expert Opinion on Pharmacotherapy·Sarah L Mason, Roger A Barker
May 21, 2009·Expert Opinion on Emerging Drugs·Sarah L Mason, Roger A Barker
Nov 29, 2007·Expert Opinion on Investigational Drugs·Edward C Stack, Robert J Ferrante
Apr 10, 2013·Free Radical Biology & Medicine·Rajnish K Chaturvedi, M Flint Beal
Aug 23, 2007·ILAR Journal·Shilpa RamaswamyJeffrey H Kordower
Nov 24, 2016·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C M Lopes-RamosI Lopes-Cendes
Nov 22, 2016·Medicinal Research Reviews·Sofia EstevesPatrícia Maciel
May 17, 2007·Cell Transplantation·Shilpa RamaswamyJeffrey H Kordower
Dec 1, 2009·Pharmaceuticals·Michelangelo MancusoGabriele Siciliano
Dec 9, 2017·American Journal of Medical Genetics. Part a·Audrey S Dickey, Albert R La Spada
Sep 13, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Liliana Menalled, Daniela Brunner
Jul 9, 2008·Current Opinion in Neurology·Emmanuel RozeJocelyne Caboche
Aug 5, 2009·Journal of Neurochemistry·Peter O Bauer, Nobuyuki Nukina
Dec 17, 2008·Annals of the New York Academy of Sciences·Rajnish K Chaturvedi, M Flint Beal
Dec 17, 2008·Annals of the New York Academy of Sciences·Edward C StackRobert J Ferrante
Apr 29, 2008·Genome Génome / Conseil National De Recherches Canada·Sepehr Bahadorani, Arthur J Hilliker
Jul 24, 2013·Journal of Neurochemistry·Michael H ParkinsonPaola Giunti
Feb 18, 2016·Behavioural Pharmacology·Yah-Se K Abada, Bart A Ellenbroek
Jun 23, 2010·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Daniel J AmanteJames Rusche
Sep 14, 2017·Behavioural Pharmacology·Hanan Naeim Attia, Yousreya Aly Maklad
Jan 15, 2019·Journal of Huntington's Disease·Melanie P Jensen, Roger A Barker
Apr 4, 2019·Frontiers in Molecular Neuroscience·Bindu D Paul, Solomon H Snyder
Apr 16, 2019·Oxidative Medicine and Cellular Longevity·Sonja Stojković BurićMilica Pešić
Jan 1, 2014·Molecular and Cellular Biochemistry·J ChakrabortyK P Mohanakumar
Dec 12, 2012·Alternatives to Laboratory Animals : ATLA·Nuno H Franco, I Anna S Olsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.